Optimal timing for intravascular administration set replacement

NHMRC Centre of Research Excellence in Nursing, Centre for Health Practice Innovation, Griffith Health Institute, Griffith University, 170 Kessels Road, Brisbane, Queensland, Australia, 4111.
Cochrane database of systematic reviews (Online) (Impact Factor: 6.03). 09/2013; 9(9):CD003588. DOI: 10.1002/14651858.CD003588.pub3
Source: PubMed


The tubing (administration set) attached to both venous and arterial catheters may contribute to bacteraemia and other infections. The rate of infection may be increased or decreased by routine replacement of administration sets. This review was originally published in 2005 and was updated in 2012.
The objective of this review was to identify any relationship between the frequency with which administration sets are replaced and rates of microbial colonization, infection and death.
We searched The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 6), MEDLINE (1950 to June 2012), CINAHL (1982 to June 2012), EMBASE (1980 to June 2012), reference lists of identified trials and bibliographies of published reviews. The original search was performed in February 2004. We also contacted researchers in the field. We applied no language restriction.
We included all randomized or controlled clinical trials on the frequency of venous or arterial catheter administration set replacement in hospitalized participants.
Two review authors assessed all potentially relevant studies. We resolved disagreements between the two review authors by discussion with a third review author. We collected data for seven outcomes: catheter-related infection; infusate-related infection; infusate microbial colonization; catheter microbial colonization; all-cause bloodstream infection; mortality; and cost. We pooled results from studies that compared different frequencies of administration set replacement, for instance, we pooled studies that compared replacement ≥ every 96 hours versus every 72 hours with studies that compared replacement ≥ every 48 hours versus every 24 hours.
We identified 26 studies for this updated review, 10 of which we excluded; six did not fulfil the inclusion criteria and four did not report usable data. We extracted data from the remaining 18 references (16 studies) with 5001 participants: study designs included neonate and adult populations, arterial and venous administration sets, parenteral nutrition, lipid emulsions and crystalloid infusions. Most studies were at moderate to high risk of bias or did not adequately describe the methods that they used to minimize bias. All included trials were unable to blind personnel because of the nature of the intervention.No evidence was found for differences in catheter-related or infusate-related bacteraemia or fungaemia with more frequent administration set replacement overall or at any time interval comparison (risk ratio (RR) 1.06, 95% confidence interval (CI) 0.67 to 1.69; RR 0.67, 95% CI 0.27 to 1.70). Infrequent administration set replacement reduced the rate of bloodstream infection (RR 0.73, 95% CI 0.54 to 0.98). No evidence revealed differences in catheter colonization or infusate colonization with more frequent administration set replacement (RR 1.08, 95% CI 0.94 to 1.24; RR 1.15, 95% CI 0.70 to 1.86, respectively). Borderline evidence suggested that infrequent administration set replacement increased the mortality rate only within the neonatal population (RR 1.84, 95% CI 1.00 to 3.36). No evidence revealed interactions between the (lack of) effects of frequency of administration set replacement and the subgroups analysed: parenteral nutrition and/or fat emulsions versus infusates not involving parenteral nutrition or fat emulsions; adult versus neonatal participants; and arterial versus venous catheters.
Some evidence indicates that administration sets that do not contain lipids, blood or blood products may be left in place for intervals of up to 96 hours without increasing the risk of infection. Other evidence suggests that mortality increased within the neonatal population with infrequent administration set replacement. However, much the evidence obtained was derived from studies of low to moderate quality.

Download full-text


Available from: Donna Marianne Gillies, Sep 12, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose Previously published guidelines are available that provide comprehensive recommendations for detecting and preventing healthcare-associated infections (HAIs). The intent of this document is to highlight practical recommendations in a concise format designed to assist acute care hospitals in implementing and prioritizing their central line-associated bloodstream infection (CLABSI) prevention efforts. This document updates "Strategies to Prevent Central Line-Associated Bloodstream Infections in Acute Care Hospitals,"1 published in 2 This expert guidance document is sponsored by the Society for Healthcare Epidemiology of America (SHEA) and is the product of a collaborative effort led by SHEA, the Infectious Diseases Society of America (IDSA), the American Hospital Association (AHA), the Association for Professionals in Infection Control and Epidemiology (APIC), and The Joint Commission, with major contributions from representatives of a number of organizations and societies with content expertise. The list of endorsing and supporting organizations is presented in the introduction to the 2014 updates.2 © 2014 by The Society for Healthcare Epidemiology of America. All rights reserved.
    Infection Control and Hospital Epidemiology 07/2014; 35(7):753-771. DOI:10.1086/676533 · 4.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Vascular access devices (VADs), such as peripheral or central venous catheters, are vital across all medical and surgical specialties. To allow therapy or haemodynamic monitoring, VADs frequently require administration sets (AS) composed of infusion tubing, fluid containers, pressure-monitoring transducers and/or burettes. While VADs are replaced only when necessary, AS are routinely replaced every 3-4 days in the belief that this reduces infectious complications. Strong evidence supports AS use up to 4 days, but there is less evidence for AS use beyond 4 days. AS replacement twice weekly increases hospital costs and workload. This is a pragmatic, multicentre, randomised controlled trial (RCT) of equivalence design comparing AS replacement at 4 (control) versus 7 (experimental) days. Randomisation is stratified by site and device, centrally allocated and concealed until enrolment. 6554 adult/paediatric patients with a central venous catheter, peripherally inserted central catheter or peripheral arterial catheter will be enrolled over 4 years. The primary outcome is VAD-related bloodstream infection (BSI) and secondary outcomes are VAD colonisation, AS colonisation, all-cause BSI, all-cause mortality, number of AS per patient, VAD time in situ and costs. Relative incidence rates of VAD-BSI per 100 devices and hazard rates per 1000 device days (95% CIs) will summarise the impact of 7-day relative to 4-day AS use and test equivalence. Kaplan-Meier survival curves (with log rank Mantel-Cox test) will compare VAD-BSI over time. Appropriate parametric or non-parametric techniques will be used to compare secondary end points. p Values of <0.05 will be considered significant. Relevant ethical approvals have been received. CONSORT Statement recommendations will be used to guide preparation of any publication. Results will be presented at relevant conferences and sent to the major organisations with clinical practice guidelines for VAD care. Australian New Zealand Clinical Trial Registry (ACTRN 12610000505000). Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to
    BMJ Open 02/2015; 5(2):e007257-e007257. DOI:10.1136/bmjopen-2014-007257 · 2.27 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Riassunto. Introduzione. Le sepsi correlate a catetere vascolare (SCV) hanno una incidenza elevata in terapia intensiva. Obiettivo. Verificare l'incidenza di SCV in una popolazione di pazienti ricoverati in terapia intensiva (TI) prima e dopo l'introduzione delle linee guida CDC 2011. Metodi. Studio osservazionale retrospettivo sui pazienti ricoverati da Gennaio 2009 a Dicembre 2013 in una TI polivalente. Per i primi 30 mesi le linee di infusione e monitoraggio sono state cambiate ogni 96 ore, nei successivi 30 ogni 7 giorni. In tutti i pazienti è stata utilizzata una linea infusionale chiusa mediante l'utilizzo di connettori needlefree a pressione neutra (Microclave). Sono stati considerati nello studio i seguenti presidi: catetere venoso centrale (CVC), cannula arteriosa (ART) e catetere di Swan Ganz (SG). Risultati. Nel periodo con cambio ogni 96 ore su 13395 gg/catetere si sono registrate 15 SCV, con densità di incidenza di 1.12 infezioni per 1000 gg/catetere. Nel periodo con cambio delle linee ogni 7 giorni, su 13.120 giorni/catetere totali si sono sviluppate 11 SCV (0.83 infezioni per 1000 giorni/catetere). La riduzione delle SCV è stata statisticamente significativa per i cateteri SG (4.17 vs. nessuna infezione, p=0.02), mentre per i CVC (1.12 vs 1.45 - p= 0.37) e le ART (0.35 vs 0.36 - p=0.61) il tasso è rimasto invariato. Conclusioni. Sostituire le linee infusionali ogni 7 giorni non ha determinato un aumento delle SCV, contribuendo a ridurre i costi di gestione per paziente.
    Assistenza infermieristica e ricerca: AIR 10/2015; 34(3):125-133. · 0.32 Impact Factor
Show more